Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haluska

Showing results (311-320 of 366) with videos related to

Pageof 37
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2012
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcomaM M Mita, E Poplin, C D Britten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine TherapyWilliam J Gradishar, Denise A Yardley, Rachel Layman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanomaRobert Soiffer, F Stephen Hodi, Frank Haluska, et al.
Archives of Surgery (Chicago, Ill. : 1960)|April 13, 1999
Outcome of patients with melanoma and histologically negative sentinel lymph nodesM A Gadd, A B Cosimi, J Yu, et al.
The New England Journal of Medicine|May 1, 2004
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibThomas J Lynch, Daphne W Bell, Raffaella Sordella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology GroupLawrence E Flaherty, Megan Othus, Michael B Atkins, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Gynecologic Oncology|July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaRichard T Penson, Kathleen M Moore, Gini F Fleming, et al.
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
Pageof 37

Showing results (311-320 of 366) with videos related to

Sort By:
Pageof 37
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2012
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcomaM M Mita, E Poplin, C D Britten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine TherapyWilliam J Gradishar, Denise A Yardley, Rachel Layman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanomaRobert Soiffer, F Stephen Hodi, Frank Haluska, et al.
Archives of Surgery (Chicago, Ill. : 1960)|April 13, 1999
Outcome of patients with melanoma and histologically negative sentinel lymph nodesM A Gadd, A B Cosimi, J Yu, et al.
The New England Journal of Medicine|May 1, 2004
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibThomas J Lynch, Daphne W Bell, Raffaella Sordella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology GroupLawrence E Flaherty, Megan Othus, Michael B Atkins, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Gynecologic Oncology|July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaRichard T Penson, Kathleen M Moore, Gini F Fleming, et al.
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
Pageof 37